Detalhe da pesquisa
1.
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
Blood
; 137(9): 1196-1207, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32871588
2.
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.
Blood
; 132(9): 948-961, 2018 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29967129
3.
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
Haematologica
; 99(7): 1191-6, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24705186
4.
Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.
Br J Clin Pharmacol
; 71(2): 199-206, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21219400
5.
AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth.
Oncogene
; 40(3): 603-617, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33203990
6.
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Hematol Oncol
; 28(2): 82-8, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19768693
7.
Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
Hematol Oncol
; 27(4): 190-7, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19274615
8.
Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation.
Int J Hematol
; 96(1): 47-57, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22610512
9.
Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.
Leuk Res
; 33(9): 1260-5, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19201023
10.
Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.
Leuk Lymphoma
; 50(6): 944-51, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19479613